

IN THE CLAIMS

Please cancel claims 34, 38, 40-42, 49 and 50 without prejudice to Applicants' right to pursue the subject matter of these claims. Please amend claims 31, 36, 37, 39, 44, 45, 47 and 48 as follows:

1. – 30. (CANCELED)

31. (CURRENTLY AMENDED) A synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and which comprises the a nucleotide sequence shown in SEQ ID NO: 10 selected from the group consisting of TGACGTCA and SEQ ID NOS: 1-4, 6-12, 14-15, 18-101, 103, 105, 107 and 109, wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

32. – 35. (CANCELED)

36. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 34, wherein the oligonucleotide is 45 up to 70 nucleotides in length.

37. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 34, wherein the oligonucleotide is 45 up to 50 nucleotides in length, and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, 18-101, 103, 105, 107 and 109.

38. (CANCELED)

39. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 34, wherein the oligonucleotide is 30 nucleotides in length, and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, 18-101, 103, 105, 107 and 109.

40. (CANCELED)

41. (CANCELED)
42. (CANCELED)
43. (WITHDRAWN) A pharmaceutically acceptable salt of a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.
44. (WITHDRAWN AND AMENDED) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 31 ~~34~~.
45. (WITHDRAWN AND AMENDED) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 32 ~~41~~.
46. (PREVIOUSLY PRESENTED) A composition comprising a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide, and a pharmaceutically acceptable carrier.
47. (WITHDRAWN AND AMENDED) A composition comprising the synthetic oligonucleotide of claim 31 ~~34~~ and a pharmaceutically acceptable carrier.
48. (WITHDRAWN AND AMENDED) A composition comprising the synthetic oligonucleotide of claim 39 ~~44~~ and a pharmaceutically acceptable carrier.
49. (CANCELED)
50. (CANCELED)